J. Pawlotsky

Hepatology · 2005–2020

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom J. Pawlotsky trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Lavanchy
  2. J. Feld
  3. Kris V. Kowdley
  4. María E. Reig1 , 2
  5. G. Guyatt
  6. Laurent Castéra
  7. Asociacion Latinoamericana para el Estudio del Higado

Papers from J. Pawlotsky's perspective

Ordered by how strongly the researchers J. Pawlotsky trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Sofosbuvir for previously untreated chronic hepatitis C infection. (New England Journal of Medicine)
  2. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (New England Journal of Medicine)
  3. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (New England Journal of Medicine)
  4. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (New England Journal of Medicine)
  5. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive… (The Lancet)
  6. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (New England Journal of Medicine)
  7. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination… (The Lancet)
  8. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. (Journal of Clinical Epidemiology)
  9. Sampling variability of liver fibrosis in chronic hepatitis C (Hepatology)
  10. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (Gastroenterology)

Their papers